Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)

Leadiant Biosciences

Status: Completed

Conditions: Cerebrotendinous Xanthomatoses

Treatments: Drug: Chenodeoxycholic Acid

Study type: Observational

Funder types: Industry

Identifiers

NCT05499026

CDCA-STUK-15-001

Details and patient eligibility

About

Retrospective study of CTX patients to investigate the safety and clinical efficacy of Chenodeoxycholic Acid

Enrollment: 28 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

Diagnosis of CTX Received treatment with CDCA Age between 2 and 75 years Having at least one cholestanol level and/or urinary bile alcohol level no more than 3 months prior to treatment with CDCA and one cholestanol level and/or urinary bile alcohol level post-treatment within 2 years from the beginning of therapy with CDCA

Exclusion criteria